Comprehensive registry of esophageal cancer in Japan, 2014

• Published in: Esophagus : official journal of the Japan Esophageal Society 2022-01, Vol.19 (1), p.1-26
• Main Authors: Watanabe, Masayuki, Toh, Yasushi, Ishihara, Ryu, Kono, Koji, Matsubara, Hisahiro, Murakami, Kentaro, Muro, Kei, Numasaki, Hodaka, Oyama, Tsuneo, Ozawa, Soji, Saeki, Hiroshi, Tanaka, Koji, Tsushima, Takahiro, Ueno, Masaki, Uno, Takashi, Yoshio, Toshiyuki, Usune, Shiyori, Takahashi, Arata, Miyata, Hiroaki
• Format: Article
• Language: English
• Subjects: Cancer surgery; Carcinoma, Squamous Cell - pathology; Chemotherapy; Clinical outcomes; Endoscopy; Epidemiology; Esophageal cancer; Esophageal Neoplasms - pathology; Esophagectomy; Gastroenterology; Humans; Japan - epidemiology; Medicine; Medicine & Public Health; Radiation therapy; Registries; Special; Special Article; Surgical Oncology; Thoracic Surgery
• ISSN: 1612-9059; 1612-9067
• DOI: 10.1007/s10388-021-00879-1

Background The registration committee for esophageal cancer in the Japan Esophageal Society (JES) has collected the patients' characteristics, treatment, and outcomes annually. Methods We analyzed the data of patients who had visited the participating hospitals in 2014. We collected the data with a web-based data collection system using the National Clinical Database. We used the Japanese Classification of Esophageal Cancer 10th edition by JES and the TNM classification 7th edition by the Union of International Cancer Control (UICC) for cancer staging. Results A total of 9026 cases were registered from 344 institutions in Japan. Squamous cell carcinoma and adenocarcinoma accounted for 87.9% and 7.1%, respectively. The 5-year survival rates of patients treated using endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, and esophagectomy were 87.1%, 33.7%, 25.3%, and 59.3%, respectively. Esophagectomy was performed in 5204 cases. Concerning the approach used for esophagectomy, 48.1% of the cases were treated thoracoscopically. The operative mortality (within 30 days after surgery) was 0.75%, and the hospital mortality was 2.0%. The survival curves showed an excellent discriminatory ability both in the clinical and pathologic stages by the JES system. The survival of pStage IV was better than IIIC in the UICC system, because pStage IV included the patients with supraclavicular lymph-node metastasis (M1 LYM). Conclusion We hope that this report contributes to improving all aspects of diagnosing and treating esophageal cancer in Japan.